P/E ratio for Genetic Technologies (GENE)
P/E ratio as of April 2024 (TTM): N/A
According to Genetic Technologies's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2007 the company had a P/E ratio of -14.8.
P/E ratio history for Genetic Technologies from 2005 to 2010
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2007 | -14.8 | 60.32% |
| 2006 | -9.23 | -35.16% |
| 2005 | -14.2 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Thermo Fisher Scientific TMO | 37.3 | N/A | 🇺🇸 USA |
 Quest Diagnostics
DGX | 20.0 | N/A | 🇺🇸 USA |
 Danaher DHR | 30.6 | N/A | 🇺🇸 USA |
 LabCorp LH | 26.4 | N/A | 🇺🇸 USA |
 Compugen CGEN | -4.75 | N/A | 🇮🇱 Israel |
 Neogen NEOG | -100 | N/A | 🇺🇸 USA |
 Myriad Genetics MYGN | -5.91 | N/A | 🇺🇸 USA |
 Eterna Therapeutics ERNA | -0.3077 | N/A | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.